FDA kicked off reauthorization negotiations for the Biosimilar User Fee Act (BsUFA) in December 2015, when the first public meeting was held on the subject. More recently, FDA met with various industry professionals last month to discuss various topics regarding the negotiations. The meeting, which took place in mid-March 2016, was held in order to:
FDA started out the meeting with an overview of the statutory provisions for the BsUFA reauthorization process. Also at the meeting’s outset, the Agency presented a proposed timeline for the negotiations’ completion. Industry parties responded to this timeline with “an estimate of the time needed for their respective organizations to review a draft package of proposed recommendations following the face-to-face negotiations, to further inform the development of a timeline for future discussions.”
During the meeting, FDA outlined its experiences during the first three years of BsUFA and highlighted its goals and enhancements for the reauthorization of BsUFA II, which were backed with summaries of the associated proposals. Among these goals, FDA included:
Industry representatives also provided their perspectives for the reauthorization of BsUFA II, which include:
Biotechnology Industry Organization (BIO) & Pharmaceutical Research and Manufacturers of America (PhRMA) [presented jointly] –
In response to these perspectives, FDA asked the industry parties to coordinate their respective proposals in order to develop one unified set. The Agency asked that this be done by the time of the group’s next meeting.
During the meeting, attendees also worked to establish a set of ground rules to govern the BsUFA reauthorization negotiations. At this time, FDA proposed a set a rules, which were agreed upon by everyone in attendance. Nonetheless, “it was acknowledged that the more detailed discussion surrounding any of the original high-level proposals may warrant introduction of new components under such proposals at a later date.”
At the close of the discussion the next meeting was set, which was scheduled to be held on March 24, 2016. FDA has not yet published any information regarding the events of the arranged meeting. It will be very interesting to watch as FDA continues to progress through the BsUFA II reauthorization negotiations, especially with the Agency’s recent approval of Inflectra™ (infliximab-dyyb), the second US biosimilar product.
Our regulatory group specializes in all things pertaining to an FDA submission and can help get your product approved by the Agency in the most time and cost effective manner. To learn more about our services, contact us today.
April 13, 2016
On Friday, April 8th, the FDA announced revisions to the labeling of metformin, the prescription drug for type 2 diabetes. Metformin is an oral medication that helps control blood sugar levels in...
April 13, 2016
On Monday, January 4th, the FDA released two final orders which increased the regulation of surgical mesh used to repair pelvic organ prolapse (POP). The orders were developed in order to strengthen...
April 13, 2016
On Monday, March 6th, the FDA announced plans to hold a public meeting regarding the development of patient-focused drugs for autism. In the notice published in the Federal Register, the FDA notes...